Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of danicopan added to C5 inhibitors in PNH
2023-504867-18-00Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs) and serious TEAEs. Started Jul 2024; status: completed.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2023-504867-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504867-18-00.